Drugs Containing Excipient (Inactive Ingredient) STREPTOMYCIN SULFATE

Generic drugs containing STREPTOMYCIN SULFATE excipient

Company	Ingredient	NDC	Excipient
Sanofi Vaccines US Inc	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	49281-564	STREPTOMYCIN SULFATE

Streptomycin Sulfate Market Dynamics and Financial Trajectory

Last updated: August 9, 2026

Streptomycin sulfate is an active pharmaceutical ingredient, not a pharmaceutical excipient. Its commercial market is a mature, low-growth injectable antibiotic segment driven by tuberculosis programs, limited hospital indications, veterinary demand, and public-sector procurement. The product has no meaningful remaining composition-of-matter patent protection. Financial performance depends more on manufacturing continuity, regulatory qualification, tender pricing, and availability than on exclusivity.

What is streptomycin sulfate used for?

Streptomycin sulfate is the sulfate salt of streptomycin, an aminoglycoside antibiotic produced through fermentation by Streptomyces griseus. It is administered primarily by intramuscular injection because oral absorption is poor.

Human uses include:

• Tuberculosis, usually in specific drug-resistant or treatment-intolerant cases
• Plague
• Tularemia
• Brucellosis
• Certain serious gram-negative infections
• Some endocarditis regimens when combined with other antibiotics

Streptomycin is no longer a routine first-line treatment for drug-susceptible tuberculosis in most modern guidelines because of toxicity, resistance, and the availability of rifampicin-, isoniazid-, pyrazinamide-, ethambutol-, fluoroquinolone-, and newer bedaquiline-based regimens. The World Health Organization has narrowed its role in tuberculosis treatment, although it remains relevant where resistance patterns, access constraints, or clinical circumstances justify its use.[1]

The product is distinct from:

• Streptomycin base, the active molecular form
• Streptomycin hydrochloride or other salts, where applicable
• Pharmaceutical excipients used in injectable formulations
• Dihydrostreptomycin, a related aminoglycoside with a separate regulatory and commercial history

How large is the streptomycin sulfate market?

No major pharmaceutical company publicly reports standalone global revenue for streptomycin sulfate. The commercial market is fragmented across active-ingredient manufacturers, contract manufacturers, government suppliers, hospital distributors, and veterinary producers. Public market reports that provide precise global revenue estimates should be treated cautiously because they often combine streptomycin API, finished injectable products, veterinary formulations, agricultural products, or broader aminoglycoside categories.

The market has four main demand pools:

Demand segment	Commercial role	Growth profile
Human injectable products	Hospitals, tuberculosis programs, infectious-disease procurement	Flat to declining in developed markets
Public-health tuberculosis supply	National programs and international tenders	Volatile, policy-dependent
Veterinary products	Livestock and companion-animal products	Stable but exposed to antimicrobial controls
Agricultural products	Limited use against selected plant bacterial diseases in some jurisdictions	Regulatory and geographically constrained

The market is therefore a volume business rather than a premium innovation market. Price competition is strongest for standard API grades and government tenders. Higher pricing can arise from short supply, validated sterile manufacturing, approved supplier status, and rapid delivery requirements.

What is driving demand for streptomycin sulfate?

Tuberculosis treatment programs

Tuberculosis remains the most important human-use demand driver. Streptomycin demand is linked to:

• Multidrug-resistant tuberculosis protocols
• National treatment guidelines
• Drug shortages involving alternative injectable agents
• Public procurement programs in lower-income countries
• Local resistance patterns
• Availability of oral alternatives

The commercial effect of tuberculosis demand is uneven. Large public tenders can create temporary volume spikes, but the product does not have a reliable long-term growth trajectory because clinical guidelines increasingly favor less toxic and more effective regimens.

Veterinary use

Veterinary demand provides a second market base. Streptomycin and related aminoglycosides have been used in livestock and companion-animal products, particularly for bacterial infections. This market faces regulatory pressure because aminoglycosides can contribute to antimicrobial resistance and raise residue concerns in food-producing animals.

The European Union applies strict controls to veterinary antimicrobial use, while other regions maintain broader access. Changes in veterinary prescription rules, withdrawal periods, residue standards, and antimicrobial stewardship programs directly affect demand.

Supply disruption and substitution

Streptomycin can experience demand increases when substitute products are unavailable. Relevant substitutes include amikacin, gentamicin, kanamycin, capreomycin, fluoroquinolones, and newer tuberculosis medicines. Substitution is clinically constrained because these products have different resistance profiles, toxicity risks, indications, and regulatory statuses.

A shortage of injectable tuberculosis drugs can temporarily increase streptomycin procurement. That effect is episodic rather than structural.

How does streptomycin sulfate compare with competing aminoglycosides?

Product	Main commercial use	Relative market position	Key constraint
Streptomycin sulfate	Tuberculosis and selected infections	Mature, declining in routine use	Ototoxicity, resistance, injectable administration
Amikacin	Serious resistant gram-negative infections and tuberculosis	More clinically differentiated	Nephrotoxicity, ototoxicity, injectable use
Gentamicin	Broad hospital and veterinary use	Larger and more diversified market	Resistance and toxicity
Tobramycin	Pseudomonas infections, including inhaled products	Supported by specialized formulations	Narrower indication
Kanamycin	Historically tuberculosis and bacterial infections	Reduced role	Resistance and toxicity
Capreomycin	Drug-resistant tuberculosis	Limited and declining	Toxicity and newer alternatives

Streptomycin has a weaker commercial position than gentamicin because gentamicin serves broader hospital and veterinary markets. It also lacks the specialized respiratory and ophthalmic delivery platforms that support some tobramycin products.

What formulations are protected by streptomycin sulfate patents?

Streptomycin sulfate is generally supplied as a sterile powder for reconstitution into an injectable solution. Formulation value is limited because the product is an old, chemically defined antibiotic with a simple dosage form.

Potentially protectable technical areas include:

• Stabilized injectable compositions
• Improved sterile powders
• Reconstitution systems
• Combination products
• Long-acting delivery systems
• Veterinary dosage forms
• Process improvements that increase purity or yield

The commercial importance of these rights is limited unless they produce a material improvement in stability, sterility assurance, administration, or manufacturing economics. Routine injectable streptomycin sulfate products are unlikely to support significant patent-based price premiums.

What is the patent status of streptomycin sulfate?

The original streptomycin patents expired decades ago. No current composition-of-matter patent should be expected to block generic production of streptomycin sulfate.

Patent category	Current commercial relevance
Original antibiotic compound	Expired
Original fermentation technology	Expired
Sulfate salt claims	Generally expired or commercially ineffective
Standard injectable formulation	Limited protection, if any
Manufacturing-process patents	Potentially relevant for specific suppliers
Combination or delivery patents	Relevant only to narrow products
Method-of-use patents	Limited because core indications are longstanding

The practical IP barriers are manufacturing know-how, regulatory documentation, quality systems, source approval, and supply continuity. These barriers can exclude suppliers from tenders even when no patent blocks entry.

When does streptomycin sulfate lose exclusivity?

Streptomycin sulfate lost core exclusivity many decades ago. The product is commercially generic and does not depend on a modern small-molecule exclusivity period.

FDA exclusivity concepts such as five-year new chemical entity exclusivity, three-year clinical-investigation exclusivity, and 180-day generic exclusivity are not meaningful drivers for the original streptomycin product today. Any remaining market protection would arise from product-specific regulatory rights, procurement contracts, manufacturing qualification, or narrow formulation claims rather than from the antibiotic molecule itself.[2]

What is the FDA regulatory status of streptomycin sulfate?

Streptomycin sulfate has a long FDA regulatory history as an injectable antibacterial product. Its regulatory position is shaped by:

• Prescription-only status
• Injectable manufacturing requirements
• Sterility and particulate controls
• Potency and impurity specifications
• Aminoglycoside toxicity warnings
• Renal and auditory monitoring
• Product-specific labeling and approved indications

Finished-dose manufacturers must comply with current good manufacturing practice requirements. API suppliers must maintain validated fermentation, purification, sulfate conversion, drying, packaging, and analytical-control processes.

The main regulatory risk is not a patent challenge. It is failure to meet quality, sterility, impurity, traceability, or supply requirements.

What is the Orange Book status of streptomycin sulfate?

The FDA Orange Book is relevant to approved finished dosage forms, not to API ownership by itself. Streptomycin sulfate products may have historical or current listings depending on the specific product, applicant, marketing status, and FDA database treatment.

The practical Orange Book analysis is:

1. Core molecule patents are not expected to block generic manufacture.
2. Any listed patent must be reviewed at the specific finished-product level.
3. A listed method-of-use patent would matter only if it covers the proposed labeling.
4. A generic applicant could rely on an ANDA pathway where an eligible reference product and applicable FDA requirements exist.
5. API suppliers usually face qualification and supply-chain issues rather than Orange Book litigation.

A company evaluating market entry must separate API registration from finished injectable approval. The commercial risk profile is different for each.

Which companies are challenging streptomycin sulfate exclusivity?

There is no active, widely recognized exclusivity contest comparable to a Paragraph IV dispute involving a recently approved blockbuster drug. Streptomycin sulfate is a mature generic product with multiple historical and regional suppliers.

Competitive entry typically occurs through:

• New API source qualification
• ANDA or equivalent generic applications
• National registrations outside the United States
• Government tender participation
• Veterinary product approvals
• Contract manufacturing arrangements

Paragraph IV litigation is not the central market-entry mechanism. A new entrant is more likely to face FDA deficiency letters, source qualification delays, bioequivalence or product-quality requirements, tender exclusion, or customer concentration than a meaningful patent lawsuit.

How is streptomycin sulfate manufactured?

Streptomycin sulfate is manufactured through microbial fermentation followed by recovery and purification. The principal technical steps include:

1. Fermentation of a suitable Streptomyces production strain
2. Removal of biomass and process impurities
3. Isolation and concentration of streptomycin
4. Conversion to the sulfate salt
5. Drying and milling
6. Sterile or controlled packaging, depending on the intended grade
7. Release testing for potency, identity, impurities, water content, microbiological quality, and residual contaminants

Manufacturing economics depend on fermentation yield, batch size, energy consumption, downstream recovery, labor, environmental controls, and reject rates. The sulfate conversion step is not normally the primary source of differentiation. Fermentation performance and consistent impurity control are more important.

Manufacturing barriers include:

• Qualified production strains
• Fermentation reproducibility
• Contamination control
• Validated impurity methods
• Regulatory inspection history
• Documentation for international registrations
• Reliable sterile finishing capacity

What is the financial trajectory for streptomycin sulfate?

The financial trajectory is mature and structurally constrained.

Financial factor	Expected effect
Human tuberculosis demand	Supports baseline volume but does not create strong growth
Declining routine use	Reduces developed-market demand
Veterinary restrictions	Limits expansion and creates regional volatility
Generic competition	Compresses API and finished-product prices
Tender procurement	Creates volume but reduces margins
Supply shortages	Can produce temporary price increases
Manufacturing consolidation	May improve utilization for efficient suppliers
Regulatory compliance	Raises fixed costs and favors established producers
New delivery technology	Limited near-term effect on standard products

The strongest suppliers are likely to be those with low-cost fermentation, broad regulatory files, reliable quality systems, and access to public-health or veterinary tenders. Producers that depend on spot sales of unqualified API face greater price and volume volatility.

Public-company revenue exposure is generally immaterial or undisclosed because streptomycin sulfate is usually one product within a broader anti-infectives, API, or contract-manufacturing portfolio. A supplier’s financial performance should therefore be assessed through segment margins, plant utilization, regulatory inspection outcomes, customer concentration, and tender wins rather than through reported streptomycin revenue alone.

What generic launch scenarios exist for streptomycin sulfate?

Base case: stable, low-growth supply

Existing suppliers retain public-health and veterinary accounts. Prices remain competitive, and demand tracks tuberculosis procurement and regional veterinary policy.

Downside case: continued clinical displacement

Greater use of oral and newer tuberculosis therapies reduces injectable demand. Veterinary restrictions further narrow the market. Lower volumes increase the importance of manufacturing scale.

Short-term upside case: supply disruption

A manufacturing failure, regulatory action, or shortage of substitute injectables produces temporary demand and pricing power. The effect is unlikely to persist after alternative supply returns.

Strategic upside case: qualified niche supply

A supplier with regulatory approvals, reliable delivery, and access to government tenders can build a defensible niche despite low molecule-level barriers. The advantage comes from execution rather than patent exclusivity.

What patent litigation affects streptomycin sulfate?

Current commercial risk is more likely to arise from regulatory and contractual disputes than patent litigation. Relevant issues include:

• API specification disputes
• Batch failures
• Sterility or contamination findings
• Product recalls
• GMP inspection actions
• Tender disqualification
• Supply-contract termination
• Trademark or labeling disputes
• Veterinary residue enforcement

A patent search remains appropriate for a specific new formulation, combination, delivery system, or manufacturing process. It is unlikely to identify a broad patent barrier to conventional streptomycin sulfate API production.

How strong is the streptomycin sulfate patent estate?

The patent estate is weak for standard API and injectable products. Its commercial strength can be summarized as follows:

Asset type	Patent strength	Business impact
Core molecule	None in practical terms	No exclusivity
Sulfate salt	Low	Limited blocking power
Standard injection	Low	Generic competition
Fermentation process	Low to moderate	May protect a particular process
Novel delivery system	Moderate if technically distinct	Narrow product protection
Combination therapy	Case-specific	Depends on claim scope and labeling
Manufacturing know-how	Often commercially important	Not equivalent to patent exclusivity

Key Takeaways

• Streptomycin sulfate is an API, not an excipient.
• The product is a mature generic antibiotic with expired core exclusivity.
• Tuberculosis programs and veterinary use support demand, but clinical and regulatory substitution limits growth.
• Publicly disclosed standalone revenue is generally unavailable.
• API pricing is driven by fermentation economics, tenders, supplier qualification, and shortages.
• Patent litigation and Paragraph IV challenges are not central current risks.
• Manufacturing quality, regulatory compliance, and delivery reliability create more commercial protection than patents.
• The financial outlook is stable to declining, with occasional short-term pricing increases during supply disruptions.
• A new entrant’s strongest strategy is regulatory qualification and tender access, not patent enforcement.

FAQs About Streptomycin Sulfate Market Entry

Is streptomycin sulfate still commercially important?

Yes, but mainly in selected tuberculosis, infectious-disease, veterinary, and public-sector markets. Its role is smaller than that of broader-use aminoglycosides such as gentamicin.

Can a company manufacture streptomycin sulfate without a license from the original innovator?

Core molecule and original-use patent rights have expired. A company still needs applicable regulatory approvals, GMP-compliant manufacturing, and market-specific product registrations.

Is streptomycin sulfate included in the FDA Orange Book?

The Orange Book analysis depends on the specific finished dosage form and applicant listing. The API itself is not protected by a current core patent estate.

Does streptomycin sulfate have biosimilar competition?

No. Biosimilar rules apply to biological products. Streptomycin sulfate is a chemically defined small-molecule antibiotic and competes through generic-drug pathways.

What is the largest commercial risk for a streptomycin sulfate supplier?

The largest risks are demand erosion, tender-price compression, regulatory noncompliance, batch failure, and loss of qualified customers. Patent infringement is generally a secondary risk for conventional products.

References

1. World Health Organization. (2022). WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment. World Health Organization.

2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2023). Current good manufacturing practice for drugs. U.S. Department of Health and Human Services.

4. World Health Organization. (2023). WHO model list of essential medicines, 23rd list. World Health Organization.

5. U.S. National Library of Medicine. (2024). DailyMed: Streptomycin sulfate injection product labeling. National Library of Medicine.